Hyloris partner AFT licenses Maxigesic IV rights in mainland China to Chengdu Tongde

PUBT · 1d ago
Hyloris partner AFT licenses Maxigesic IV rights in mainland China to Chengdu Tongde
  • Hyloris partner AFT Pharmaceuticals signed an exclusive license with Chengdu Tongde Pharma for Maxigesic IV in mainland China.
  • Tongde will fund and run CMC work, clinical trials, and regulatory activities to seek China approval for the IV pain treatment.
  • Upon approval, Tongde will manufacture and commercialize Maxigesic IV, paying net-sales royalties to AFT with a minority share flowing to Hyloris.
  • The deal replaces a prior China license for Maxigesic IV that was terminated ahead of the new agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyloris Developments SA published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.